During the past decade, mass spectrometry, notably LC/MS, has become a major approach to identify and quantify proteins in patient samples. It includes analysis before treatments to find the proper biomarkers for cancers diagnostics, and monitoring of the arising of the anti-drug antibodies in human plasma after therapies. Despite the fact that MS has pretty high sensitivity and specificity, research in biotherapeutics requires even more. Immunocapture, and so specific protein enrichment, offer an interesting immunoassay solution. Here, we present simple to use and efficient reagents to improve the immunocapture and thus the output of the MS technology. [Read more…]
Challenges and limitations of ADC development
One of the major challenges of modern medicine is to find a safe cancer therapy. The Food and Drug Administration has approved Adcetris® (brentuximab vedotin) and Kadcyla® (ado-trastuzumab emtansine) that are considered as powerful treatments against cancer. They are good examples of antibody-drug conjugates (ADCs). The principle is to link a drug, that can be cytotoxic, to an antibody able to target cancer cells. Unfortunately, the development of ADCs faces some difficulties. Indeed, depending on the method for the conjugation, the ADC can be highly heterogenous. [Read more…]
Exploring the small RNA transcriptome, a key challenge
Small RNA are involved in numerous biological process and linked to a wide range of conditions. For example miRNA can be used for detection of cancers from blood samples and are used for cancer classification. They are involved in the regulation of the messenger RNA translation.
The small RNA transcriptome is a vast world rich in information. There are not only miRNA but other small RNA that can also be used for diagnostics. For example, Repetto et al in 2015 (doi: 10.1186/s12916-015-0489-y) discovered novel small RNA in blood, s-RNY1-5p as a diagnostic biomarker for atherosclerosis-related diseases. The authors used small-RNA sequencing with the innovative CleanTag technology.
Biomolecule conjugation is critical to many applications such as bead-based assays, ELISA and chromatography by affinity. Unfortunately the classical methods are known to be tedious and with low efficiency. Trilink Biotechnologies has come this year with the solution, an innovative chromophore-linker-based conjugation chemistry called ChromaLink. [Read more…]
Capping is a required protection in 5′ of the mRNA that is necessary for biological activity and stability into the cells. There are already several methods of capping using mCap, ARCA or enzymatic methods. Unfortunately, they are limited in efficiency (such as mCap and ARCA), and can be costly (such as the enzymatic methods). Trilink Biotechnologies, the modified nucleic acid experts, have developped a new, far more efficient technology called CleanCap available in Europe via tebu-bio. [Read more…]
As messenger RNAs (mRNAs) are easier to deliver into cells than plasmids or viral vectors, they are useful for non-dividing cells. Inversely to the vectors, they ensure genome integrity that is recommended for cell therapeutics. mRNA are also well adapted to transient expression as required for cellular reprogramming, gene editing, and vaccines.
You might like to take a look at this poster, presented by Trilink (renowned modified nucleic acid experts) at the Keystone symposia last March (Pattern Recognition Signaling: From Innate Immunity to Inflammatory Disease). They share results on how to optimize messenger RNA for therapeutic activity.
“Innate Immune focused approaches to maximize messenger RNA therapeutic activity”
Download your copy of the poster here.
mRNAs are expression factors that mimic fully processed mRNA. Being the substrate for translation by ribosomes, mRNA expression factors are often preferred over viral vectors for cell reprogramming and iPS cell generation because of the absent risk of integration into the genome. Such RNA-induced pluripotent stem cells (RiPSCs described in 2010 by Warren et al.) are becoming more and more popular. 3 reasons might illustrate RiPSCs’ attractivty.